Vnitr Lek 2018, 64(10):928-933 | DOI: 10.36290/vnl.2018.129

Angiotensin-converting enzyme inhibitor-induced angioedema: epidemiology, pathogenesis and management

Marta Sobotková
Ústav imunologie 2. LF UK a FN Motol, Praha

Angiotensin-converting enzyme-induced angioedema occurs in 0.1-0.7 % of recipients. Swelling often affects head and neck and makes it an extremely dangerous adverse effect. Bradykinin is considered to be the main mediator of edema in these cases. There is currently no specific treatment for angioedema of this etiology. Drugs used for treatment of attacks in hereditary angioedema with C1 inhibitor deficiency are tried also in this indication, but there are currently no clinical studies available supporting their effectiveness. Patients using angiotensin-converting enzyme inhibitors with angioedemas of unknown etiology must discontinue using this drug. Swelling episodes may appear even after this arrangement.

Keywords: angioedema; angiotensin-converting enzyme inhibitors; bradykinin

Received: February 23, 2018; Accepted: March 28, 2018; Published: October 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sobotková M. Angiotensin-converting enzyme inhibitor-induced angioedema: epidemiology, pathogenesis and management. Vnitr Lek. 2018;64(10):928-933. doi: 10.36290/vnl.2018.129.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2011; 13(9): 667-675. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1751-7176.2011.00508.x>. Go to original source... Go to PubMed...
    2. Bas M, Greve J, Strassen U et al. Angioedema induced by cardiovascular drugs: new players join old friends. Allergy 2015; 70(10): 1196-1200. Dostupné z DOI: <http://dx.doi.org/10.1111/all.12680>. Go to original source... Go to PubMed...
    3. Yusuf S, Teo K, Anderson C et al. [Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators]. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372(9644): 1174-1183. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(08)61242-8>. Erratum in Lancet.2008; 372(9647): 1384. Go to original source... Go to PubMed...
    4. Cicardi M, Suffritti C, Perego F et al. Novelties in the Diagnosis and Treatment of Angioedema. J Investig Allergol Clin Immunol 2016; 26: 212-221; quiz two pages after page 221. Dostupné z DOI: <http://dx.doi.org/10.18176/jiaci.0087> Go to original source... Go to PubMed...
    5. Cicardi M, Aberer W, Banerji A et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69(5): 602-616. Dostupné z DOI: <http://dx.doi.org/10.1111/all.12380>. Go to original source... Go to PubMed...
    6. Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature. J Clin Hypertens (Greenwich) 2017; 19(12): 1377-1382. Dostupné z DOI: <http://dx.doi.org/10.1111/jch.13097>. Go to original source... Go to PubMed...
    7. Hakl R. Současné možnosti léčby hereditárního angioedému. Vnitř Lék 2016; 62(9): 736-739. Go to PubMed...
    8. Zuraw BL The Pathophysiology of Hereditary Angioedema. World Allergy Organ J 2010; 3(9 Suppl): S25-S28. Dostupné z DOI: <http://dx.doi.org/10.1097/WOX.0b013e3181f3f21c>. Go to original source... Go to PubMed...
    9. Guyer ACH, Banejri A. ACE inhibitor-induced angioedema. Dostupné z WWW: <https://www.uptodate.com/contents/ace-inhibitor-induced-angioedema>.
    10. Banerji A, Blumenthal KG, Lai KH et al. Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record. J Allergy Clin Immunol Pract 2017; 5(3): 744-749. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaip.2017.02.018>. Go to original source... Go to PubMed...
    11. Hahn J, Trainotti S, Hoffmann TK et al. Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report. Am J Case Rep 2017; 18: 576-579. Go to original source... Go to PubMed...
    12. Kostis JB, Packer M, Black HR et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17(2): 103-111. Go to original source... Go to PubMed...
    13. Morimoto T, Gandhi TK, Fiskio JM et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10(4): 499-509. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365-2753.2003.00484.x>. Go to original source... Go to PubMed...
    14. Brown NJ, Ray WA, Snowden M et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60(1): 8-13. Dostupné z DOI: <http://dx.doi.org/10.1016/S0009-9236(96)90161-7>. Go to original source... Go to PubMed...
    15. Kostis JB, Kim HJ, Rusnak J et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165(14): 1637-1642. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.165.14.1637>. Go to original source... Go to PubMed...
    16. Byrd JB, Woodard-Grice A, Stone E et al. Association of angiotensin-converting enzyme inhibitor-associated angioede ma with transplant and immunosuppressant use. Allergy 2010; 65(11): 1381-1387. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1398-9995.2010.02398.x>. Go to original source... Go to PubMed...
    17. Bernstein JA, Cremonesi P, Hoffmann TK et al. Angioedema in the emergency department: a practical guide to differential diagnosis and management. Int J Emerg Med 2017; 10(1): 15. Dostupné z DOI: <http://dx.doi.org/10.1186/s12245-017-0141-z>. Go to original source... Go to PubMed...
    18. Kalambay J, Ghazanfar H, Martes Pena KA et al. Pathogenesis of Drug Induced Non-Allergic Angioedema: A Review of Unusual Etiologies. Cureus 2017; 9(8): e1598. Dostupné z DOI: <http://dx.doi.org/10.7759/cureus.1598>. Go to original source... Go to PubMed...
    19. Liška M. Vyšetřovací metody v alergologii. Postgraduální medicína 2012; 14(2): 122-128.
    20. Sobotková M. Současné možnosti léčby hereditárního angioedému. Farmakoterapeutická revue 2017; 3: 155-160.
    21. Baş M, Greve J, Stelter K et al. A Randomized Trial of Icatibant in ACE-Inhibitor-Induced Angioedema. N Engl J Med 2015; 372(5): 418-425. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1312524>. Go to original source... Go to PubMed...
    22. Straka BT, Ramirez CE, Byrd JB et al. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. J Allergy Clin Immunol 2017; 140(1): 242-248. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2016.09.051>. Go to original source... Go to PubMed...
    23. Sinert R, Levy P, Bernstein JA et al. Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema. J Allergy Clin Immunol Pract 2017; 5: 1402-1409.e3. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaip.2017.03.003>. Go to original source... Go to PubMed...
    24. Greve J, Bas M, Hoffmann TK et al. Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope 2015; 125(6): E198-E202. Dostupné z DOI: <http://dx.doi.org/10.1002/lary.25113>. Go to original source... Go to PubMed...
    25. Bernstein JA, Moellman JJ, Collins SP et al. Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department. Ann Allergy Asthma Immunol 2015; 114(3): 245-249. Dostupné z DOI: <http://dx.doi.org/10.1016/j.anai.2014.12.007>. Go to original source... Go to PubMed...
    26. Lewis LM, Graffeo C, Crosley P et al. Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial. Ann Emerg Med 2015; 65(2): 204-213. Dostupné z DOI: <http://dx.doi.org/10.1016/j.annemergmed.2014.07.014>. Go to original source... Go to PubMed...
    27. Beltrami L, Zanichelli A, Zingale L et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29(11): 2273-2277. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e32834b4b9b>. Go to original source... Go to PubMed...
    28. Makani H, Messerli FH, Romero J et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 2012; 110(3): 383-391. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2012.03.034>. Go to original source... Go to PubMed...
    29. Anzaldua DA, Schmitz PG. Aliskiren as an alternative in a patient with life-threatening ACE inhibitor-induced angioedema. Am J Kidney Dis 2008; 51(3): 532-533. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2007.11.035>. Go to original source... Go to PubMed...
    30. Bork K, Wulff K, Steinmüller-Magin L et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy 2018; 73(2): 442-450. Dostupné z DOI: <http://dx.doi.org/10.1111/all.13270>. Go to original source... Go to PubMed...
    31. Bafunno V, Firinu D, D'Apolito M et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 2018; 141(3): 1009-1017. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2017.05.020>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.